Skip to content
HowShorted

Relay Therapeutics, Inc. short interest in 2025

In 2025, Relay Therapeutics, Inc.'s disclosed short interest ran from 9.09% of shares outstanding on 15 Jan 2025 to 12.83% on 31 Dec 2025, a change of +3.74 percentage points. The year's high was 13.51% on 15 May 2025 and its low 9.09% on 15 Jan 2025, averaging 11.92% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 24.37 days on 29 Aug 2025. Full history: Relay Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Relay Therapeutics, Inc. in 2025

2025 in figures

Start of year
9.09% (15 Jan 2025)
End of year
12.83% (31 Dec 2025)
Change
+3.74 pp
High
13.51% (15 May 2025)
Low
9.09% (15 Jan 2025)
Average
11.92%
Highest days to cover
24.37 (29 Aug 2025)
SEC filings marked
8

Every report in 2025

Relay Therapeutics, Inc. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 20259.09%4.66
31 Jan 20259.36%6.48
14 Feb 20259.43%13.09
28 Feb 20259.67%8.8810-K filed, results (8-K)
14 Mar 202511.42%7.54
31 Mar 202510.79%6.74
15 Apr 202510.97%5.48
30 Apr 202511.63%9.32
15 May 202513.51%8.1410-Q filed, results (8-K)
30 May 202513.21%16.24
13 Jun 202513.14%15.82
30 Jun 202512.55%11.79
15 Jul 202512.55%16.84
31 Jul 202513.05%6.25
15 Aug 202513.19%11.2010-Q filed, results (8-K)
29 Aug 202513.18%24.37
15 Sep 202513.05%15.01
30 Sep 202513.13%12.58
15 Oct 202512.72%13.96
31 Oct 202510.31%8.42
14 Nov 202512.33%8.3110-Q filed, results (8-K)
28 Nov 202513.36%10.93
15 Dec 202511.71%10.19
31 Dec 202512.83%9.53

See also: Relay Therapeutics, Inc.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.